http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 29 Apr 2026 06:09:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++3++++++++++MESOBLAST+LTD+++++++++++++For%3A+Mar+18++Filed+by%3A+COBLEY+LYNETTE+ELIZABETH/26387337.html si-local-file:///var/storage/secattach/20260429/26387337.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++MESOBLAST+LTD+++++++++++++For%3A+Mar+18++Filed+by%3A+COBLEY+LYNETTE+ELIZABETH/26387337.html Wed, 29 Apr 2026 06:09:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++MESOBLAST+LTD+++++++++++++For%3A+Mar+18++Filed+by%3A+COBLEY+LYNETTE+ELIZABETH/26387337.html si-local-file:///var/storage/secattach/20260429/26387337.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++MESOBLAST+LTD+++++++++++++For%3A+Mar+18++Filed+by%3A+COBLEY+LYNETTE+ELIZABETH/26387337.html Wed, 29 Apr 2026 06:09:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++MESOBLAST+LTD+++++++++++++For%3A+Mar+18++Filed+by%3A+COBLEY+LYNETTE+ELIZABETH/26387337.html si-local-file:///var/storage/secattach/20260429/26387337.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++MESOBLAST+LTD+++++++++++++For%3A+Mar+18++Filed+by%3A+COBLEY+LYNETTE+ELIZABETH/26387337.html Wed, 29 Apr 2026 06:09:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/FDA/Mesoblast+completes+patient+recruitment+for+phase+3+chronic+back+pain+trial/26386006.html <p>Mesoblast Limited (NASDAQ: MESO; ASX: MSB) announced that its phase 3 clinical trial evaluating rexlemestrocel-L for chronic low back pain associated with degenerative disc disease has reached its patient recruitment target of at least 300 participants.</p> <p>The placebo-controlled study will follow patients randomized to receive either a single intra-discal injection of rexlemestrocel-L or a sham control for 12 months. The trial aims to confirm results from an earlier study where the treatment resulted in reductions in pain and opioid usage for up to three years.</p> <p>The primary endpoint measures reduction of low back pain at 12 months compared to sham controls. Secondary http://www.streetinsider.com/FDA/Mesoblast+completes+patient+recruitment+for+phase+3+chronic+back+pain+trial/26386006.html Tue, 28 Apr 2026 20:53:30 -0400 A.25360159 MESO MSB O.01273089 O.29339306 http://www.streetinsider.com/FDA/Mesoblast+completes+patient+recruitment+for+phase+3+chronic+back+pain+trial/26386006.html <p>Mesoblast Limited (NASDAQ: MESO; ASX: MSB) announced that its phase 3 clinical trial evaluating rexlemestrocel-L for chronic low back pain associated with degenerative disc disease has reached its patient recruitment target of at least 300 participants.</p> <p>The placebo-controlled study will follow patients randomized to receive either a single intra-discal injection of rexlemestrocel-L or a sham control for 12 months. The trial aims to confirm results from an earlier study where the treatment resulted in reductions in pain and opioid usage for up to three years.</p> <p>The primary endpoint measures reduction of low back pain at 12 months compared to sham controls. Secondary http://www.streetinsider.com/FDA/Mesoblast+completes+patient+recruitment+for+phase+3+chronic+back+pain+trial/26386006.html Tue, 28 Apr 2026 20:53:30 -0400 A.25360159 MESO MSB O.01273089 O.29339306 http://www.streetinsider.com/FDA/Mesoblast+completes+patient+recruitment+for+phase+3+chronic+back+pain+trial/26386006.html <p>Mesoblast Limited (NASDAQ: MESO; ASX: MSB) announced that its phase 3 clinical trial evaluating rexlemestrocel-L for chronic low back pain associated with degenerative disc disease has reached its patient recruitment target of at least 300 participants.</p> <p>The placebo-controlled study will follow patients randomized to receive either a single intra-discal injection of rexlemestrocel-L or a sham control for 12 months. The trial aims to confirm results from an earlier study where the treatment resulted in reductions in pain and opioid usage for up to three years.</p> <p>The primary endpoint measures reduction of low back pain at 12 months compared to sham controls. Secondary http://www.streetinsider.com/FDA/Mesoblast+completes+patient+recruitment+for+phase+3+chronic+back+pain+trial/26386006.html Tue, 28 Apr 2026 20:53:30 -0400 A.25360159 MESO MSB O.01273089 O.29339306 http://www.streetinsider.com/FDA/Mesoblast+completes+patient+recruitment+for+phase+3+chronic+back+pain+trial/26386006.html <p>Mesoblast Limited (NASDAQ: MESO; ASX: MSB) announced that its phase 3 clinical trial evaluating rexlemestrocel-L for chronic low back pain associated with degenerative disc disease has reached its patient recruitment target of at least 300 participants.</p> <p>The placebo-controlled study will follow patients randomized to receive either a single intra-discal injection of rexlemestrocel-L or a sham control for 12 months. The trial aims to confirm results from an earlier study where the treatment resulted in reductions in pain and opioid usage for up to three years.</p> <p>The primary endpoint measures reduction of low back pain at 12 months compared to sham controls. Secondary http://www.streetinsider.com/FDA/Mesoblast+completes+patient+recruitment+for+phase+3+chronic+back+pain+trial/26386006.html Tue, 28 Apr 2026 20:53:30 -0400 A.25360159 MESO MSB O.01273089 O.29339306 http://www.streetinsider.com/FDA/Mesoblast+completes+patient+recruitment+for+phase+3+chronic+back+pain+trial/26386006.html <p>Mesoblast Limited (NASDAQ: MESO; ASX: MSB) announced that its phase 3 clinical trial evaluating rexlemestrocel-L for chronic low back pain associated with degenerative disc disease has reached its patient recruitment target of at least 300 participants.</p> <p>The placebo-controlled study will follow patients randomized to receive either a single intra-discal injection of rexlemestrocel-L or a sham control for 12 months. The trial aims to confirm results from an earlier study where the treatment resulted in reductions in pain and opioid usage for up to three years.</p> <p>The primary endpoint measures reduction of low back pain at 12 months compared to sham controls. Secondary http://www.streetinsider.com/FDA/Mesoblast+completes+patient+recruitment+for+phase+3+chronic+back+pain+trial/26386006.html Tue, 28 Apr 2026 20:53:30 -0400 A.25360159 MESO MSB O.01273089 O.29339306 http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html <p align="justify">NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemestrocel-L for the treatment of chronic low back pain (CLBP) associated with degenerative disc disease has achieved its patient recruitment target. This marks a significant milestone in Mesoblast’s plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration.</p> <p align="justify">The placebo-controlled study (MSB-DR004) will follow at least 300 patients randomized to a single intra-discal injection of rexlemestrocel-L or http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html Tue, 28 Apr 2026 20:53:00 -0400 A.25360159 MESO MSB O.01273089 O.29339306 http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html <p align="justify">NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemestrocel-L for the treatment of chronic low back pain (CLBP) associated with degenerative disc disease has achieved its patient recruitment target. This marks a significant milestone in Mesoblast’s plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration.</p> <p align="justify">The placebo-controlled study (MSB-DR004) will follow at least 300 patients randomized to a single intra-discal injection of rexlemestrocel-L or http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html Tue, 28 Apr 2026 20:53:00 -0400 A.25360159 MESO MSB O.01273089 O.29339306 http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html <p align="justify">NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemestrocel-L for the treatment of chronic low back pain (CLBP) associated with degenerative disc disease has achieved its patient recruitment target. This marks a significant milestone in Mesoblast’s plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration.</p> <p align="justify">The placebo-controlled study (MSB-DR004) will follow at least 300 patients randomized to a single intra-discal injection of rexlemestrocel-L or http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html Tue, 28 Apr 2026 20:53:00 -0400 A.25360159 MESO MSB O.01273089 O.29339306 http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html <p align="justify">NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemestrocel-L for the treatment of chronic low back pain (CLBP) associated with degenerative disc disease has achieved its patient recruitment target. This marks a significant milestone in Mesoblast’s plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration.</p> <p align="justify">The placebo-controlled study (MSB-DR004) will follow at least 300 patients randomized to a single intra-discal injection of rexlemestrocel-L or http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html Tue, 28 Apr 2026 20:53:00 -0400 A.25360159 MESO MSB O.01273089 O.29339306 http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html <p align="justify">NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemestrocel-L for the treatment of chronic low back pain (CLBP) associated with degenerative disc disease has achieved its patient recruitment target. This marks a significant milestone in Mesoblast’s plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration.</p> <p align="justify">The placebo-controlled study (MSB-DR004) will follow at least 300 patients randomized to a single intra-discal injection of rexlemestrocel-L or http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html Tue, 28 Apr 2026 20:53:00 -0400 A.25360159 MESO MSB O.01273089 O.29339306 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html <p align="justify">NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemestrocel-L for the treatment of chronic low back pain (CLBP) associated with degenerative disc disease has achieved its patient recruitment target. This marks a significant milestone in Mesoblast’s plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration.</p> <p align="justify">The placebo-controlled study (MSB-DR004) will follow at least 300 patients randomized to a single intra-discal injection of rexlemestrocel-L or http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html Tue, 28 Apr 2026 20:53:00 -0400 A.25360159 MESO MSB O.01273089 O.29339306 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html <p align="justify">NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemestrocel-L for the treatment of chronic low back pain (CLBP) associated with degenerative disc disease has achieved its patient recruitment target. This marks a significant milestone in Mesoblast’s plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration.</p> <p align="justify">The placebo-controlled study (MSB-DR004) will follow at least 300 patients randomized to a single intra-discal injection of rexlemestrocel-L or http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html Tue, 28 Apr 2026 20:53:00 -0400 A.25360159 MESO MSB O.01273089 O.29339306 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html <p align="justify">NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemestrocel-L for the treatment of chronic low back pain (CLBP) associated with degenerative disc disease has achieved its patient recruitment target. This marks a significant milestone in Mesoblast’s plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration.</p> <p align="justify">The placebo-controlled study (MSB-DR004) will follow at least 300 patients randomized to a single intra-discal injection of rexlemestrocel-L or http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html Tue, 28 Apr 2026 20:53:00 -0400 A.25360159 MESO MSB O.01273089 O.29339306 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html <p align="justify">NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemestrocel-L for the treatment of chronic low back pain (CLBP) associated with degenerative disc disease has achieved its patient recruitment target. This marks a significant milestone in Mesoblast’s plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration.</p> <p align="justify">The placebo-controlled study (MSB-DR004) will follow at least 300 patients randomized to a single intra-discal injection of rexlemestrocel-L or http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html Tue, 28 Apr 2026 20:53:00 -0400 A.25360159 MESO MSB O.01273089 O.29339306 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html <p align="justify">NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemestrocel-L for the treatment of chronic low back pain (CLBP) associated with degenerative disc disease has achieved its patient recruitment target. This marks a significant milestone in Mesoblast’s plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration.</p> <p align="justify">The placebo-controlled study (MSB-DR004) will follow at least 300 patients randomized to a single intra-discal injection of rexlemestrocel-L or http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Patient+Recruitment+Target+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26386005.html Tue, 28 Apr 2026 20:53:00 -0400 A.25360159 MESO MSB O.01273089 O.29339306 http://www.streetinsider.com/Mergers+and+Acquisitions/Mesoblast+acquires+CAR+platform+technology+to+enhance+cell+therapies/26313325.html <p>Mesoblast Limited (NASDAQ: MESO; ASX: MSB) acquired an exclusive worldwide license to a chimeric antigen receptor (CAR) technology platform for enhancing its mesenchymal stromal cell products, according to a company statement.</p> <p>The technology, developed by investigators at Mayo Clinic and published in Nature Biomedical Engineering, is designed to genetically engineer CAR constructs into mesenchymal stromal cells to improve targeted homing to inflamed tissue. Mesoblast plans to incorporate the engineered CARs to enhance target specificity and augment immunomodulation and tissue regeneration properties of its products.</p> <p>The CAR technology identifies various CAR-MSCs with potential for enhanced tissue-specific targeting in inflammatory and autoimmune diseases, including http://www.streetinsider.com/Mergers+and+Acquisitions/Mesoblast+acquires+CAR+platform+technology+to+enhance+cell+therapies/26313325.html Tue, 14 Apr 2026 20:11:18 -0400 A.07309385 MESO MSB O.01273089 O.20043539 http://www.streetinsider.com/Mergers+and+Acquisitions/Mesoblast+acquires+CAR+platform+technology+to+enhance+cell+therapies/26313325.html <p>Mesoblast Limited (NASDAQ: MESO; ASX: MSB) acquired an exclusive worldwide license to a chimeric antigen receptor (CAR) technology platform for enhancing its mesenchymal stromal cell products, according to a company statement.</p> <p>The technology, developed by investigators at Mayo Clinic and published in Nature Biomedical Engineering, is designed to genetically engineer CAR constructs into mesenchymal stromal cells to improve targeted homing to inflamed tissue. Mesoblast plans to incorporate the engineered CARs to enhance target specificity and augment immunomodulation and tissue regeneration properties of its products.</p> <p>The CAR technology identifies various CAR-MSCs with potential for enhanced tissue-specific targeting in inflammatory and autoimmune diseases, including http://www.streetinsider.com/Mergers+and+Acquisitions/Mesoblast+acquires+CAR+platform+technology+to+enhance+cell+therapies/26313325.html Tue, 14 Apr 2026 20:11:18 -0400 A.07309385 MESO MSB O.01273089 O.20043539 http://www.streetinsider.com/Mergers+and+Acquisitions/Mesoblast+acquires+CAR+platform+technology+to+enhance+cell+therapies/26313325.html <p>Mesoblast Limited (NASDAQ: MESO; ASX: MSB) acquired an exclusive worldwide license to a chimeric antigen receptor (CAR) technology platform for enhancing its mesenchymal stromal cell products, according to a company statement.</p> <p>The technology, developed by investigators at Mayo Clinic and published in Nature Biomedical Engineering, is designed to genetically engineer CAR constructs into mesenchymal stromal cells to improve targeted homing to inflamed tissue. Mesoblast plans to incorporate the engineered CARs to enhance target specificity and augment immunomodulation and tissue regeneration properties of its products.</p> <p>The CAR technology identifies various CAR-MSCs with potential for enhanced tissue-specific targeting in inflammatory and autoimmune diseases, including http://www.streetinsider.com/Mergers+and+Acquisitions/Mesoblast+acquires+CAR+platform+technology+to+enhance+cell+therapies/26313325.html Tue, 14 Apr 2026 20:11:18 -0400 A.07309385 MESO MSB O.01273089 O.20043539 http://www.streetinsider.com/Mergers+and+Acquisitions/Mesoblast+acquires+CAR+platform+technology+to+enhance+cell+therapies/26313325.html <p>Mesoblast Limited (NASDAQ: MESO; ASX: MSB) acquired an exclusive worldwide license to a chimeric antigen receptor (CAR) technology platform for enhancing its mesenchymal stromal cell products, according to a company statement.</p> <p>The technology, developed by investigators at Mayo Clinic and published in Nature Biomedical Engineering, is designed to genetically engineer CAR constructs into mesenchymal stromal cells to improve targeted homing to inflamed tissue. Mesoblast plans to incorporate the engineered CARs to enhance target specificity and augment immunomodulation and tissue regeneration properties of its products.</p> <p>The CAR technology identifies various CAR-MSCs with potential for enhanced tissue-specific targeting in inflammatory and autoimmune diseases, including http://www.streetinsider.com/Mergers+and+Acquisitions/Mesoblast+acquires+CAR+platform+technology+to+enhance+cell+therapies/26313325.html Tue, 14 Apr 2026 20:11:18 -0400 A.07309385 MESO MSB O.01273089 O.20043539 http://www.streetinsider.com/Mergers+and+Acquisitions/Mesoblast+acquires+CAR+platform+technology+to+enhance+cell+therapies/26313325.html <p>Mesoblast Limited (NASDAQ: MESO; ASX: MSB) acquired an exclusive worldwide license to a chimeric antigen receptor (CAR) technology platform for enhancing its mesenchymal stromal cell products, according to a company statement.</p> <p>The technology, developed by investigators at Mayo Clinic and published in Nature Biomedical Engineering, is designed to genetically engineer CAR constructs into mesenchymal stromal cells to improve targeted homing to inflamed tissue. Mesoblast plans to incorporate the engineered CARs to enhance target specificity and augment immunomodulation and tissue regeneration properties of its products.</p> <p>The CAR technology identifies various CAR-MSCs with potential for enhanced tissue-specific targeting in inflammatory and autoimmune diseases, including http://www.streetinsider.com/Mergers+and+Acquisitions/Mesoblast+acquires+CAR+platform+technology+to+enhance+cell+therapies/26313325.html Tue, 14 Apr 2026 20:11:18 -0400 A.07309385 MESO MSB O.01273089 O.20043539 http://www.streetinsider.com/Press+Releases/Mesoblast+Acquires+Chimeric+Antigen+Receptor+%28CAR%29+Platform+Technology+for+Precision-Enhanced+Cell+Products/26313323.html <p align="justify">NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell (MSC) products. Mesoblast plans to incorporate the engineered CARs to further boost effectiveness of Mesoblast&apos;s products, with the goal of enhancing the target specificity and augmenting inherent properties of immunomodulation and tissue regeneration.</p> <p align="justify">Mesoblast’s MSC technology platforms, including the first and only FDA-approved MSC product in http://www.streetinsider.com/Press+Releases/Mesoblast+Acquires+Chimeric+Antigen+Receptor+%28CAR%29+Platform+Technology+for+Precision-Enhanced+Cell+Products/26313323.html Tue, 14 Apr 2026 20:10:00 -0400 A.07309385 MESO MSB O.01273089 O.20043539 http://www.streetinsider.com/Press+Releases/Mesoblast+Acquires+Chimeric+Antigen+Receptor+%28CAR%29+Platform+Technology+for+Precision-Enhanced+Cell+Products/26313323.html <p align="justify">NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell (MSC) products. Mesoblast plans to incorporate the engineered CARs to further boost effectiveness of Mesoblast&apos;s products, with the goal of enhancing the target specificity and augmenting inherent properties of immunomodulation and tissue regeneration.</p> <p align="justify">Mesoblast’s MSC technology platforms, including the first and only FDA-approved MSC product in http://www.streetinsider.com/Press+Releases/Mesoblast+Acquires+Chimeric+Antigen+Receptor+%28CAR%29+Platform+Technology+for+Precision-Enhanced+Cell+Products/26313323.html Tue, 14 Apr 2026 20:10:00 -0400 A.07309385 MESO MSB O.01273089 O.20043539